X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q1 2024 Earnings Call Transcript
X4 Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.25884 EPS, expectations were $-0.17. X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals Inc (XFOR)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | OrbiMed Advisors Samuel Isaly | 7,133,515 | $4,137,439 | 0.08% | |
| 2. | Kingdon Capital Mark Kingdon | 4,623,683 | $2,681,736 | +34% | 0.28% |
| 3. | Adage Capital Management Phill Gross And Robert Atchinson | 4,276,315 | $2,480,263 | 0% | |
| 4. | Soleus Capital Guy Levy | 4,051,000 | $2,349,580 | -12% | 0.2% |
| 5. | Perceptive Advisors Joseph Edelman | 3,545,454 | $2,056,363 | 0.04% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.20 | 25,000 | Director | 76,667 | 2023-08-18 | Filing | |
| $10.00 | 20,000 | Large Shareholder | 370,454 | 2017-11-20 | Filing | |
| $10.00 | 300,000 | Large Shareholder | 867,639 | 2017-11-20 | Filing | |
| $10.00 | 300,000 | Director | 867,639 | 2017-11-20 | Filing | |
| $10.00 | 16,552 | Large Shareholder | 1,868,961 | 2017-11-20 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.56 | 31,897 | Officer, Director | 1,025,816 | 2024-10-15 | Filing | |
| $0.55 | 230,645 | Officer | 0 | 2024-10-07 | Filing | |
| $0.58 | 11,127 | Officer | 48,509 | 2024-10-07 | Filing | |
| $0.55 | 239,436 | Officer, Director | 1,057,713 | 2024-10-07 | Filing | |
| $0.57 | 67,695 | Officer | 452,060 | 2024-10-07 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 16,915,784 | $14,183,885 | 1.35% | |
| 2. | 14,986,793 | $12,566,426 | 0.83% | |
| 3. | 8,417,524 | $7,058,094 | 0% | |
| 4. | 8,008,865 | $6,715,432 | 0% | |
| 5. | 3,073,532 | $2,577,157 | 0% |
News See All
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2023 Earnings Call Transcript
X4 Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.1, expectations were $-0.15.
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q3 2023 Earnings Call Transcript
Operator: Greetings and welcome to X4 Pharmaceuticals’ Third Quarter Financial and Operating Results Conference Call. At this time all participants are in a listen-only mode.
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q2 2023 Earnings Call Transcript
Operator: Greetings. Welcome to X4 Pharmaceuticals' Second Quarter 2023 Financial and Operating Results Conference Call. [Operator Instructions] As a reminder, the conference call is being recorded.
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q1 2023 Earnings Call Transcript
Operator: Greetings, and welcome to X4 Pharmaceuticals' First Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, the conference call is being recorded.
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2022 Earnings Call Transcript
Operator: Thank you for standing by. This is the conference operator. Welcome to X4 Pharmaceuticals Fourth Quarter and Full Year 2022 Earnings Conference Call.
10 Best Healthcare Stocks Under $20 According to Michael Castor's Sio Capital
In this article, we discuss the 10 best healthcare stocks under $20 according to Michael Castor's Sio Capital.
Is XFOR A Good Stock To Buy Now?
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter.
Do Hedge Funds Love X4 Pharmaceuticals, Inc. (XFOR)?
In this article you are going to find out whether hedge funds think X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) is a good investment right now.
Hedge Funds Staying Clear Of X4 Pharmaceuticals, Inc. (XFOR)
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November.
Billionaire Hedge Funds
